166 related articles for article (PubMed ID: 14565649)
1. Thalidomide for the treatment of acute myeloid leukemia.
Steins MB; Bieker R; Padró T; Kessler T; Kienast J; Berdel WE; Mesters RM
Leuk Lymphoma; 2003 Sep; 44(9):1489-93. PubMed ID: 14565649
[TBL] [Abstract][Full Text] [Related]
2. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
Steins MB; Padró T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM
Blood; 2002 Feb; 99(3):834-9. PubMed ID: 11806984
[TBL] [Abstract][Full Text] [Related]
4. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H
Br J Haematol; 2003 Nov; 123(3):436-41. PubMed ID: 14617002
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide.
Kreuter M; Steins M; Woelke K; Buechner T; Berdel WE; Mesters RM
Eur J Haematol; 2007 Nov; 79(5):392-7. PubMed ID: 17916085
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
7. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Padró T; Ruiz S; Bieker R; Bürger H; Steins M; Kienast J; Büchner T; Berdel WE; Mesters RM
Blood; 2000 Apr; 95(8):2637-44. PubMed ID: 10753845
[TBL] [Abstract][Full Text] [Related]
8. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
[TBL] [Abstract][Full Text] [Related]
9. [Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Mödder U
Radiologe; 2002 Mar; 42(3):222-30. PubMed ID: 11963240
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide: when everything old is new again.
Nirenberg A
Clin J Oncol Nurs; 2001; 5(1):15-8. PubMed ID: 11899395
[TBL] [Abstract][Full Text] [Related]
12. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
13. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lenalidomide in myelodysplastic syndromes.
List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide as a novel treatment of acute myeloid leukemia.
Chen Y; Borthakur G
Expert Opin Investig Drugs; 2013 Mar; 22(3):389-97. PubMed ID: 23316859
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
Cancer; 2006 Aug; 107(4):767-72. PubMed ID: 16826578
[TBL] [Abstract][Full Text] [Related]
20. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
Betticher DC; Huxol H; Müller R; Speck B; Nissen C
Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]